Susquehanna International Group
PCSA icon

Susquehanna International Group’s Processa Pharmaceuticals PCSA Stock Holding History

Susquehanna International Group’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-56
Closed -$14K – 12714
2023
Q2 		$14K Buy
+56
New +$16.5K ﹤0.01% 11710

Other funds holding PCSA

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.62B AUM 36.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Susquehanna International Group's PCSA Position: Q3 2023 in Review

Susquehanna International Group sold out of Processa Pharmaceuticals (PCSA) in Q3 2023, closing a stake of 56 shares — an estimated $14K sold.

Susquehanna International Group first reported a position in PCSA in Q2 2023 and held it in 1 quarter. The position peaked at $14K in Q2 2023. 18 funds tracked by Wall St. Rank hold PCSA as of Q3 2023.

  • Susquehanna International Group reported no remaining Processa Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Susquehanna International Group sold 56 Processa Pharmaceuticals shares in Q3 2023, an estimated $14K.
  • Susquehanna International Group first reported a position in Processa Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Susquehanna International Group's Processa Pharmaceuticals position peaked at $14K in Q2 2023.
  • 18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.